Id |
Subject |
Object |
Predicate |
Lexical cue |
T200 |
0-73 |
Sentence |
denotes |
Temporal changes in immune cell populations occur during COVID-19 disease |
T201 |
74-165 |
Sentence |
denotes |
A key question for hospitalized COVID-19 patients is how immune responses change over time. |
T202 |
166-377 |
Sentence |
denotes |
Thus, we used the global tSNE projections of overall CD8 T cell, CD4 T cell, and B cell differentiation states to interrogate temporal changes in these populations between D0 and D7 of hospitalization (Fig. 5A). |
T203 |
378-594 |
Sentence |
denotes |
Combining data for all patients revealed considerable stability of the tSNE distributions between D0 and D7 in CD8 T cell, CD4 T cell, and B cell populations, particularly for key regions of interest discussed above. |
T204 |
595-793 |
Sentence |
denotes |
For example, for CD8 T cells, the region of the tSNE map containing KI67+ and CD38+HLA-DR+ CD8 T cell populations that was enriched in COVID-19 patients at D0 (Fig. 2) was preserved at D7 (Fig. 5A). |
T205 |
794-887 |
Sentence |
denotes |
A similar temporal stability of CD4 T cell and B cell activation was also observed (Fig. 5A). |
T206 |
888-970 |
Sentence |
denotes |
Fig. 5 Temporal relationships between immune responses and disease manifestation. |
T207 |
971-1158 |
Sentence |
denotes |
(A) Global viSNE projection of non-naïve CD8 T cells, non-naïve CD4 T cells, and B cells for all subjects pooled, with cells from COVID-19 patients at D0 and D7 concatenated and overlaid. |
T208 |
1159-1430 |
Sentence |
denotes |
Frequencies of (B) KI67+ and HLA-DR+CD38+ CD4 T cells, (C) KI67+ and HLA-DR+CD38+ CD8 T cells, or (D) PBs as indicated for healthy donor (HD; green), recovered donor (RD; blue), or COVID-19 patients (red) with paired samples at D0 and D7 indicated by the connecting line. |
T209 |
1431-1536 |
Sentence |
denotes |
Significance determined by paired Wilcoxon test: *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001. |
T210 |
1537-1799 |
Sentence |
denotes |
Longitudinal patterns (see Methods) of (E) HLA-DR+CD38+ CD4 T cells or (F) PBs in COVID-19 patients shown as frequency and representative flow cytometry plots. (G) Spearman correlations of clinical parameters with longitudinal fold changes in immune populations. |
T211 |
1800-1928 |
Sentence |
denotes |
Given this apparent stability between D0 and D7, we next investigated temporal changes in lymphocyte subpopulations of interest. |
T212 |
1929-2239 |
Sentence |
denotes |
Although there were no obvious temporal changes in major phenotypically defined CD4 and CD8 T cell or B cell subsets, including plasmablasts (Fig. 5D), the frequencies of HLA-DR+CD38+ and KI67+ non-naïve CD4 (Fig. 5B) and KI67+ non-naïve CD8 T cells were statistically increased at D7 compared to D0 (Fig. 5C). |
T213 |
2240-2419 |
Sentence |
denotes |
However, in all cases, these temporal patterns were complex, with frequencies of subpopulations in individual patients appearing to increase, decrease, or stay the same over time. |
T214 |
2420-2590 |
Sentence |
denotes |
To quantify these inter-patient changes, we used a previously described data set (46) to define the stability of populations of interest in healthy individuals over time. |
T215 |
2591-2770 |
Sentence |
denotes |
We then used the range of this variation over time to identify COVID-19 patients with changes in immune cell subpopulations beyond that expected in healthy subjects (see methods). |
T216 |
2771-2966 |
Sentence |
denotes |
Using this approach, ~50% of patients had an increase in HLA-DR+CD38+ non-naïve CD4 T cells over time, whereas in ~30% of patients, these cells were stable and, in ~20%, they decreased (Fig. 5E). |
T217 |
2967-3057 |
Sentence |
denotes |
For KI67+ non-naïve CD8 T cells, there were no individuals in whom the response decreased. |
T218 |
3058-3157 |
Sentence |
denotes |
Instead, this proliferative CD8 T cell response stayed stable (~70%) or increased (~30%; fig. S6A). |
T219 |
3158-3338 |
Sentence |
denotes |
Notably, for patients in the stable category, the median frequency of KI67+ non-naïve CD8 T cells was ~10%, almost 5-fold higher than the ~1% detected for HD and RD subjects (Figs. |
T220 |
3339-3421 |
Sentence |
denotes |
5C and 2E), suggesting a sustained CD8 T cell proliferative response to infection. |
T221 |
3422-3613 |
Sentence |
denotes |
A similar pattern was observed for HLA-DR+CD38+ non-naïve CD8 (fig. S6B), where only ~10% of patients had a decrease in this population, whereas ~65% were stable and ~25% increased over time. |
T222 |
3614-4014 |
Sentence |
denotes |
The high and even increasing activated or proliferating CD8 and CD4 T cell responses over ~1 week during acute viral infection contrasted with the sharp peak of KI67 in CD8 and CD4 T cells during acute viral infections, including smallpox vaccination with live vaccinia virus (47), live attenuated yellow fever vaccine YFV-17D (48), acute influenza virus infection (49), and acute HIV infection (35). |
T223 |
4015-4130 |
Sentence |
denotes |
Approximately 42% of patients had sustained PB responses, at high levels (>10% of B cells) in many cases (Fig. 5F). |
T224 |
4131-4292 |
Sentence |
denotes |
Thus, some patients displayed dynamic changes in T cell or B cell activation over 1 week in the hospital, but there were also other patients who remained stable. |
T225 |
4293-4484 |
Sentence |
denotes |
In the latter case, some patients remained stable without clear activation of key immune populations whereas others had stable T and or B cell activation or numerical perturbation (fig. S6C). |
T226 |
4485-4677 |
Sentence |
denotes |
We next asked whether these T and B cell dynamics related to clinical measures of COVID-19 disease, by correlating changes in immune features from D0 to D7 with clinical information (Fig. 5G). |
T227 |
4678-4724 |
Sentence |
denotes |
These analyses revealed distinct correlations. |
T228 |
4725-4967 |
Sentence |
denotes |
Decreases in all populations of responding CD4 and CD8 T cells (HLA-DR+CD38+, KI67+, or activated cTfh) between D0 and D7 were positively correlated with PMN and WBC counts, suggesting a relationship between T cell activation and lymphopenia. |
T229 |
4968-5071 |
Sentence |
denotes |
Furthermore, decreases in CD4 and CD8 HLA-DR+CD38+ T cells positively correlated with APACHE III score. |
T230 |
5072-5177 |
Sentence |
denotes |
However, stable HLA-DR+CD38+ CD4 T cell responses correlated with coagulation complications and ferritin. |
T231 |
5178-5292 |
Sentence |
denotes |
Whereas decreasing activated cTfh over time was related to co-infection, the opposite pattern was observed for PB. |
T232 |
5293-5574 |
Sentence |
denotes |
Increases in proliferating KI67+ CD4 and CD8 T cells over time were positively correlated to increasing anti-SARS-CoV2 antibody from day 0 to day 7, suggesting that some individuals might have been hospitalized during the expansion phase of the antiviral immune response (Fig. 5G). |
T233 |
5575-5678 |
Sentence |
denotes |
Finally, neither Remdesivir nor HCQ treatment correlated with any of these immune features in Fig. 5G). |
T234 |
5679-5894 |
Sentence |
denotes |
Examining categorical rather than continuous clinical data, 80% of patients with decreasing PB over time had hyperlipidemia, whereas only 20% of patients with increasing PB over time had this comorbidity (fig. S6D). |
T235 |
5895-6159 |
Sentence |
denotes |
All patients who had decreasing CD38+HLA-DR+ CD8 T cells from day 0 to day 7 were treated with early vasoactive medication or inhaled nitric oxide whereas these treatments were less common for patients with stable or increasing CD38+HLA-DR+ CD8 T cells (fig. S6E). |
T236 |
6160-6322 |
Sentence |
denotes |
In contrast, vasoactive medication, inhaled nitric oxide, and early steroid treatment were equally common in patients with increasing or decreasing PB (fig. S6D). |
T237 |
6323-6430 |
Sentence |
denotes |
Similar patterns were apparent for other T cell populations and these categorical clinical data (fig. S6F). |
T238 |
6431-6566 |
Sentence |
denotes |
Thus, the trajectory of change in the T and B cell response in COVID-19 patients was strongly connected to clinical metrics of disease. |